AbCellera Biologics (ABCL) Gross Profit (2021 - 2023)

AbCellera Biologics (ABCL) has 3 years of Gross Profit data on file, last reported at $9.2 million in Q4 2023.

• Quarterly Gross Profit fell 54.21% year-over-year to $9.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $38.0 million (down 90.93% YoY) and the FY2024 annual result came in at $28.8 million, down 24.17% from the prior year.
• Gross Profit improved to $9.2 million in Q4 2023, from $6.6 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $271.9 million in Q1 2022 to a low of $5.5 million in Q3 2021.
• A 3-year average of $65.6 million and a median of $22.0 million in 2021 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 1468.32% — and 2023, when it plunged 95.52%.
• Tracing ABCL's Gross Profit over 3 years: stood at $117.4 million in 2021, then plunged by 82.93% to $20.0 million in 2022, then plunged by 54.21% to $9.2 million in 2023.
• The last three Gross Profit figures came in at $9.2 million (Q4 2023), $6.6 million (Q3 2023), and $10.1 million (Q2 2023), per Business Quant data.